Physicochemical Properties
Molecular Formula | C10H13NO6 |
Molecular Weight | 243.21 |
Exact Mass | 243.074 |
CAS # | 23205-42-7 |
PubChem CID | 54684286 |
Appearance | Off-white to light yellow solid powder |
Density | 1.718g/cm3 |
Boiling Point | 528ºC at 760mmHg |
Melting Point | 233-235ºC |
Flash Point | 273.1ºC |
Vapour Pressure | 0mmHg at 25°C |
Index of Refraction | 1.706 |
LogP | -1.8 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 2 |
Heavy Atom Count | 17 |
Complexity | 379 |
Defined Atom Stereocenter Count | 4 |
SMILES | C1=CN(C(=O)C=C1O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O |
InChi Key | CBOKZNLSFMZJJA-PEBGCTIMSA-N |
InChi Code | InChI=1S/C10H13NO6/c12-4-6-8(15)9(16)10(17-6)11-2-1-5(13)3-7(11)14/h1-3,6,8-10,12-13,15-16H,4H2/t6-,8-,9-,10-/m1/s1 |
Chemical Name | 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxypyridin-2-one |
HS Tariff Code | 2934.99.9001 |
Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
Targets | Cytidine triphosphate synthase[1] |
ln Vitro | 3-Deazauridine (DAUR) has superior anti-tumor properties when applied to L1210 leukemia cells [1]. |
ln Vivo | 3-Deazauridine (DAUR) (250 mg/kg/day; intraperitoneally; days 1–9) inhibits L1210 leukemia cells in mice with modest efficacy [1]. 3-Deazauridine (intraperitoneal injection; 5 doses): In beagle dogs and rhesus monkeys, the lethal doses are 250 mg/kg/day and 417 mg/kg/day, respectively; the lowest toxic doses are 62.5 mg/kg/day and 104 mg/kg/day, while the non-toxic doses are 31.25 mg/kg/day and 52 mg/kg/day, respectively[1]. |
References |
[1]. 3-Deazauridine (NSC 126849): an interesting modulator of biochemical response. Invest New Drugs. 1986;4(1):67-84. |
Additional Infomation |
3-Deazauridine is a N-glycosyl compound. 3-Deazauridine is a synthetic analogue of nucleoside uridine lacking a ring nitrogen in the 3-position. 3-deazauridine inhibits cytidine synthase, thereby reducing intracellular levels of cytidine and deoxycytidine and disrupting DNA and RNA synthesis. This agent may trigger apoptosis and enhance differentiation of neoplastic cells.(NCI04) 4-Hydroxy-1-(beta-D-ribofuranosyl)-2-pyridinone. Analog of uridine lacking a ring-nitrogen in the 3-position. Functions as an antineoplastic agent. |
Solubility Data
Solubility (In Vitro) | DMSO : 100 mg/mL (411.17 mM) |
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2 mg/mL (8.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (8.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 4.1117 mL | 20.5584 mL | 41.1167 mL | |
5 mM | 0.8223 mL | 4.1117 mL | 8.2233 mL | |
10 mM | 0.4112 mL | 2.0558 mL | 4.1117 mL |